Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience.

Savas Volkan KisiogluAhmet Suat DemirDamla TufekciYasemin Emur GunayHulya CoskunOzge UcuncuIrfan NuhogluMustafa KocakSerdar KarakullukcuHalil Onder Ersoz

Published in: International journal of clinical practice (2021)

Both twice-daily IDegAsp ± bolus insulin and IGlarU300 basal bolus insulin therapies are effective and safe treatment modalities.

Keyphrases

type diabetes
glycemic control
stem cells
metabolic syndrome
skeletal muscle